¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"signal loss"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • signal homogeneity
    ½ÅÈ£±ÕÁú¼º
  • signal intensity
    ½ÅÈ£°­µµ
  • signal oversampling
    ½ÅÈ£°ú´ÙÃßÃâ
  • signal peptide
    ½ÅÈ£ÆéƼµå
  • signal sequence
    ½ÅÈ£¼ø¼­
  • signal stimulus
    ½ÅÈ£ÀÚ±Ø
  • signal symptom
    Á¶ÁüÁõ»ó
  • signal transduction
    ½ÅÈ£Àü´Þ
  • signal-to-noise ratio
    ½ÅÈ£´ëÀâÀ½ºñ
  • audiometric hearing loss
    û·Â¼Ò½Ç
  • abrasion loss
    ¸¶¸ê·®, ¸¶¸ð·®
  • allowable blood loss
    Çã¿ë½ÇÇ÷·®, Çã¿ëÇ÷¾×»ó½Ç·®
  • blood loss
    ½ÇÇ÷, Ç÷¾×»ó½Ç
  • conductive hearing loss
    ÀüÀ½³­Ã», Àüµµ³­Ã»
  • congenital hereditary hearing loss
    ¼±ÃµÀ¯Àü³­Ã»
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • low signal
    Àú½ÅÈ£, ³·Àº½ÅÈ£
  • MR signal
    ÀÚ±â°ø¸í½ÅÈ£
  • off-resonance signal
    ÀÌÅ»°ø¸í½ÅÈ£
  • signal oversampling
    ½ÅÈ£°ú´ÙÃßÃâ
  • packaging signal
    ²Ù¸®±â½ÅÈ£
  • signal peptide
    ½ÅÈ£ÆéƼµå
  • signal-to-noise ratio
    ½ÅÈ£´ëÀâÀ½ºñ
  • signal
    ½ÅÈ£
  • signal sequence
    ½ÅÈ£¼ø¼­
  • signal stimulus
    ½ÅÈ£ÀÚ±Ø
  • signal symptom
    °æ°íÁõ»ó
  • signal transduction
    ½ÅÈ£Àü´Þ
  • signal void
    ¹«½ÅÈ£
  • termination signal
    Á¾·á½ÅÈ£
  • tolerogenic signal
    ¸é¿ªÇã¿ëÀ¯¹ß½ÅÈ£
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • hearing loss
    °¨°¢½Å°æ(¼º) ³­Ã»
  • hearing loss
    ³­Ã», û·Â¼Ò½Ç, û·ÂÀå¾Ö
  • hearing loss, audiometric
    û·Â¼Õ½Ç
  • hearing loss, central
    ÁßÃß¼º û·Â¼Ò½Ç, ÁßÃß¼º ³­Ã»
  • hearing loss, conductive
    ÀüÀ½¼º ³­Ã», Àüµµ¼º ³­Ã»
  • hearing loss, congenital hereditary
    ¼±Ãµ(¼º) À¯Àü¼º ³­Ã»
  • hearing loss, familial pregressive
    °¡Á· ÁøÇà(¼º) ³­Ã»
  • hearing loss, functional
    ±â´É(¼º) ³­Ã»
  • hearing loss, idiopathic sudden
    Ư¹ß¼º µ¹¹ß(¼º)³­Ã»
  • hearing loss, mixed
    È¥ÇÕ(¼º) ³­Ã»
  • hearing loss, noise induced
    ¼ÒÀ½¼º³­Ã»
  • hearing loss, occupational
    Á÷¾÷¼º³­Ã»
  • hearing loss, perceptive
    °¨À½³­Ã»
  • hearing loss, sensorineural
    °¨°¢½Å°æ¼º ³­Ã»
  • hearing loss, speech
    ¾îÀ½Ã»·Â¼Õ½Ç
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • predictive value of control signal
    Á¦¾î<´ëÁ¶>½ÅÈ£ÀÇ ¿¹ÃøÄ¡
  • primary signal system
    ÀÏÂ÷½ÅÈ£°è(ìéó­ãáûÜ Í§).
  • quadrature signal detection
    ±¸Àû ½ÅÈ£ ŽÁö
  • satiety signal
    Æ÷¸¸ ½ÅÈ£
  • saturation of signal
    ½ÅÈ£ Æ÷È­
  • signal
    ½ÅÈ£
  • signal alteration
    ½ÅÈ£ º¯°æ
  • signal amplitude
    ½ÅÈ£ ÁøÆø
  • signal anxiety
    ½ÅÈ£ºÒ¾È.
  • signal averaging
    ½ÅÈ£ Æò±Õ
  • signal channel
    ½ÅÈ£ Åë·Î
  • signal detection theory
    ½ÅÈ£°¨ÁöÀÌ·Ð
  • signal effects
    ½Åȣȿ°ú
  • signal homogeneity
    ½ÅÈ£ ±ÕÀϼº
  • signal intensity (SI)
    ½ÅÈ£ °­µµ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • low signal intensity
    Àú½ÅÈ£°­µµ
  • MR signal
    ÀÚ±â°ø¸í½ÅÈ£
  • number of signal average [=NSA]
    ½ÅÈ£Æò±Õȸ¼ö
  • off-resonance signal
    ÀÌÅ»°ø¸í½ÅÈ£
  • quadrature signal detection
    ±¸Àû½ÅȣŽÁö
  • saturation of signal
    ½ÅÈ£Æ÷È­
  • signal
    ½ÅÈ£
  • signal alteration
    ½ÅÈ£º¯°æ
  • signal amplitude
    ½ÅÈ£ÁøÆø
  • signal averaging
    ½ÅÈ£Æò±Õ
  • signal channel
    ½ÅÈ£Åë·Î
  • signal homogeneity
    ½ÅÈ£±ÕÀϼº
  • signal intensity [=SI]
    ½ÅÈ£°­µµ
  • signal oversampling
    ½ÅÈ£°úÃßÃâ
  • signal to noise ratio [=SNR]
    ½ÅÈ£´ëÀâÀ½ºñ
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
FIS forced inspiratory spirogram; free induction signal
IROS ipsilateral routing of signal
LPFS low-pass filtered signal
MES maintenance electrolyte solution; maximal electroshock; maximal electroshock seizures; myoelectric s...
SDT sensory detection theory; right sacrotransverse [fetal position] [Lat. sacrodextra transversa]; sign...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
EWL Evaporative water loss
EWL Excess Weight Loss
G-LOC G(z)-induced loss of consciousness
HL Hearing loss
LOH Loss of Heterozygosity
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • signal peptide
    ½ÅÈ£ ÆéƼµå
  • signal symptom
    °æ°í Áõ»ó
  • signal-to-noise ratio
    ½ÅÈ£-ÀâÀ½ºñ, ½ÅÈ£´ë ¼ÒÀ½ ºñÀ²
  • abrasion loss
    ¸¶¸ê ·®
    ¸¶¸ð°¡ µÇ¾î ¼Õ½ÇµÈ ¾ç.
  • blood loss
    ½ÇÇ÷
  • breathing loss
    È£Èí ¼Õ½Ç
  • energy loss
    ¿¡³ÊÁö ¼Õ½Ç
  • evaporation loss
    Áõ¹ß ¼Õ½Ç
  • familial progressive sensorineural hearing loss
    °¡Á·¼º ÁøÇ༺ °¨°¢ ½Å°æ¼º ³­Ã»
  • fear of loss of love
    ½Ç¾Ö °øÆ÷
  • fluid loss
    ü¾× »ó½Ç, ü¾× ¼Õ½Ç
  • functional hearing loss
    ±â´É¼º ³­Ã»
  • heat loss
    ¿­ ¼Õ½Ç
  • loss
    »ó½Ç, ¼Õ½Ç, ¼Ò¸ð
  • loss of appetite
    ½Ä¿å ºÎÁø
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
signal transduction The cascade of processes by which an extracellular signal (typically a hormone or neurotransmitter) interacts with a receptor at the cell surface, causing a change in the level of a second messenger for example calcium or cyclic AMP) and ultimately effects a change in the cells functioning (for example: triggering glucose uptake or initiating cell division). Can also be applied to sensory signal transduction, for example of light at photoreceptors.
(18 Nov 1997)
signal void In magnetic resonance imaging, a region emitting no radiofrequency signal, either because there are no activated protons in the region (such as flowing blood) or because a different element predominates, particularly calcium.
(05 Mar 2000)
nuclear localization signal Short, predominantly basic amino acid sequences identified as nuclear import signals for some proteins. These sequences are believed to interact with specific receptors at nuclear pores.
(12 Dec 1998)
alveolar bone loss The resorption of bone in the supporting structures of the maxilla or mandible as a result of periodontal disease.
(12 Dec 1998)
axon loss polyneuropathy A type of polyneuropathy in which axon degeneration is the sole/predominant feature; many aetiologies, particularly toxic and metabolic; on nerve conduction studies, affects amplitudes of the responses, but does not cause conduction slowing or block.
Synonym: axonal polyneuropathy.
(05 Mar 2000)
blood loss, surgical Loss of blood during surgery.
(12 Dec 1998)
Parallel Electron Energy Loss Spectroscopy <technique> Electron energy loss spectroscopy analyses the inelastically scattered electrons present in the beam after it has been transmitted through the sample. An electron energy loss spectrum typically consists of a monatomic decreasing background on which are superimposed a number of peaks. Each peak is characteristic of the scattering process that has occurred in the sample. The peaks can be used to obtain information about the chemical composition and electronic structure of the sample. Electron energy loss spectra are acquired typically in a magnetic sector spectrometer located under the camera chamber of the transmission electron microscope. Spatial resolution is typically limited by the minimum probe diameter of the microscope. Electron energy loss spectroscopy tends to be complimentary to EDS in that it can be used to analyse very thin samples of low Z materials.
Acronym: PEELS
(05 Aug 1998)
periodontal attachment loss Loss or destruction of periodontal tissue caused by periodontitis or other destructive periodontal diseases or by injury during instrumentation. Attachment refers to the periodontal ligament which attaches to the alveolar bone. It has been hypothesised that treatment of the underlying periodontal disease and the seeding of periodontal ligament cells enable the creating of new attachment.
(12 Dec 1998)
water loss, insensible Loss of water by diffusion through the skin and by evaporation from the respiratory tract. It is so called because we do not know that we are actually losing water at the time that it is leaving the body. (guyton, textbook of medical physiology, 8th ed, p274)
(12 Dec 1998)
weight loss Decrease in existing body weight.
(12 Dec 1998)
conductive hearing loss <otolaryngology> A form of deafness that results from a blockage of the ear canal or dysfunction of the ossicles or eardrum (sound collecting apparatus).
In conductive hearing loss the auditory nerve is normal, but there exists a physical problem with the sound collecting apparatus.
(05 Jan 1998)
hair loss Hair loss may be associated with aging, hormones (androgens) or genetic predisposition. The pattern of baldness in women is different from that of men. In women there is thinning of the hair all over the scalp, but the frontal hairline is maintained. The hair loss is usually permanent. Treatment has been successful with topical minoxidil in some cases.
(13 Nov 1997)
hearing loss, bilateral Partial hearing loss in both ears.
(12 Dec 1998)
hearing loss, central Hearing loss due to central nervous system disease, anywhere in the auditory pathways from the cochlear nucleus of the pons to the auditory cortex.
(12 Dec 1998)
hearing loss, conductive Hearing loss due to interference with the acoustic transmission of sound to the cochlea. The interference is in the outer or middle ear.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • distress signal
    Á¶³­ ½ÅÈ£(sos µûÀ§)
  • fog signal
    öµµÀÇ ³ó¹« ½ÅÈ£(±Ëµµ À§¿¡ ³õ´Â Æø¸í ÀåÄ¡);¾È°³½ÅÈ£
  • home signal
    Àå³» ½ÅÈ£±â(¿ª±¸³» ÁøÀÔ ¿©ºÎ¸¦ ¾Ë¸²)
  • interval signal
    (¶óµð¿À ÇÁ·Î»çÀÌÀÇ)¼Û½Å°è¼Ó½ÅÈ£
  • signal
    ½ÅÈ£;±ºÈ£;µµÈ­¼±;¦ÆÐ¿¡°Ô º¸³»´Â ¾ÏÈ£ÀÇ ¼ö;½ÅÈ£(¿ë)ÀÇ;¶Ù¾î³­;ÈǸ¢ÇÑ;½ÅÈ£(±ºÈ£)·Î ¾Ë¸®´Ù;...ÀÇ ÀüÁ¶°¡ µÇ´Ù
  • signal tower
    (öµµÀÇ) ½ÅÈ£¼Ò
  • storm signal
    ÆøÇ³¿ì ½ÅÈ£
  • time signal
    ½Ãº¸
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á